Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 11/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 8/20 | 0.50 |
| ▸ | CHEK2 | O96017 | 7/20 | 0.50 |
| ▸ | CDC42BPA | Q5VT25 | 7/20 | 0.50 |
| ▸ | GSK3A | P49840 | 6/20 | 0.50 |
| ▸ | GSK3B | P49841 | 6/20 | 0.50 |
| ▸ | CSNK1G3 | Q9Y6M4 | 6/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 5/20 | 0.50 |
| ▸ | CSNK1G1 | Q9HCP0 | 5/20 | 0.50 |
| ▸ | PKN2 | Q16513 | 5/20 | 0.50 |
| ▸ | CSNK1G2 | P78368 | 4/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.50 |
| ▸ | PLK1 | P53350 | 4/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.50 |
| ▸ | STK17A | Q9UEE5 | 3/20 | 0.50 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.50 |
| ▸ | PIM1 | P11309 | 3/20 | 0.50 |
| ▸ | PLK3 | Q9H4B4 | 3/20 | 0.50 |
| ▸ | PRKX | P51817 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17427536 | 0.79 | CXCR2 (0.52) | PLK1CYP3A4CYP2C9MAPK1CYP2D6 | |
| SCHEMBL7913081 | 0.79 | HDAC3 (0.46) | MAPKAPK2ROCK1CSNK1G1AURKBCYP2C9 | |
| SCHEMBL7346763 | 0.78 | TDO2 (0.50) | RAD52MAPK1PRKCI | |
| SCHEMBL21597116 | 0.76 | MAPT (0.50) | ROCK1CHEK2CDC42BPAGSK3AGSK3B | |
| SCHEMBL18028562 | 0.76 | IDO1 (0.44) | MAPKAPK2PRKCZPRKCDPRKCGPRKCI | |
| SCHEMBL24872319 | 0.76 | ROCK1 (0.58) | MAPKAPK2ROCK1CHEK2CDC42BPAGSK3A | |
| SCHEMBL17427534 | 0.76 | HDAC1 (0.46) | ROCK1CHEK2CDC42BPAGSK3AGSK3B | |
| SCHEMBL7905958 | 0.76 | PLK1 (0.50) | PLK1MKNK2AURKBPRKCDCYP3A4 | |
| SCHEMBL7905834 | 0.73 | CXCR2 (0.45) | PLK1CYP3A4CYP2C9MAPK1 | |
| SCHEMBL7905856 | 0.71 | BUB1 (0.45) | MAPKAPK2ROCK1CHEK2GSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018075600-A1 | TARGETED DELIVERY OF NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | SEATTLE GENETICS, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
| WO-2009012375-A2 | SQUARATE KINASE INHIBITORS | WYETH (US) | 2009-01-22 | — | — | WO | disclosed |
| EP-1358160-A1 | AMINAL DIONES AS POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2003-11-05 | — | — | EP | disclosed |
| US-6495576-B2 | N-(1-((3,4-DIOXO-2-(3-PYRIDINYLAMINO)-1-CYCLOBUTEN-1-YL)AMINO) -2,2-DIMETHYLPROPYL)-4-METHYLBENZAMIDE FOR EXAMPLE; TREATING BLADDER OVERACTIVITY, BENIGN PROSTATIC HYPERPLASIA, PREMATURE LABOR, AND SEXUAL DISORDERS | ABBOTT LABORATORIES | 2002-12-17 | — | — | US | disclosed |
| US-20020165264-A1 | Aminal diones as potassium channel openers | ABBOTT LABORATORIES | 2002-11-07 | — | — | US | disclosed |
| WO-2002062761-A1 | AMINAL DIONES AS POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165264-A1 | Aminal diones as potassium channel openers | KCNJ2, KCNJ11, KCNH1 | MAPKAPK2 2283/4885ROCK1 4232/4885CHEK2 3694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.